Predictive value of [99mTc]Tc-MAA SPECT/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8217-8228
DOI: 10.1007/s00259-026-08079-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 11.08.2026. Verfasst von Grace Keane und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, University Medical Center, Utrecht, 3508 GA, The Netherlands. g.e.m.keane@umcutrecht.nl. Hauptthemen laut MEDLINE: Liver Neoplasms, Radioembolization, Therapeutic, Yttrium Radioisotopes, Carcinoma, Hepatocellular. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
The DOSISPHERE-01 study demonstrated a survival benefit for patients treated with 90 Y radioembolization using personalised [ 99m Tc]Tc-MAA guided versus standard dosimetry guided treatment. This ancillary analysis complements DOSISPHERE-01 by reporting post-treatment dosimetry and assessing agreement between predictive ([ 99m Tc]Tc-MAA) and post-treatment ( 90 Y) absorbed doses. Materials and methods All DOSISPHERE-01 patients with both pre-treatment [ 99m Tc]Tc-MAA SPECT/CT and post-treatment 90 Y imaging were eligible. Multicompartment dosimetry was performed using two segmentation methods: anatomic (MRI/CT) and count-threshold based (SPECT). Mean normal liver tissue and index-lesion absorbed dose, and dose volume histogram (DVH) metrics were determined using Simplicit 90 Y (Mirada Medical, Oxford UK). Agreement between [ 99m Tc]Tc-MAA and 90 Y absorbed doses was assessed via Bland-Altman and paired-sample analysis, with correlation assessed via linear-regression.
Results
Thirty-seven patients were included: 19 from the personalised arm and 18 from the standard dosimetry arm. Pre- and post-treatment absorbed dose differences were not statistically significant for the index lesion (241 Gy vs. 229 Gy, p = 0.15; mean difference 11.9 Gy; 95% LoA − 84.3 to 108.2 Gy), Perfused Volume Normal Liver Tissue (PVNT) (91 Gy vs. 99 Gy, p = 0.14; mean difference − 8.2 Gy; 95% LoA − 71.6 to 55.1 Gy), or DVH metrics (V200, D70, D50) using anatomic segmentation. Corresponding metrics were significantly different using count-threshold segmentation ( p < 0.05). For both methods, pre- and post-treatment mean index lesion and PVNT absorbed doses, and V200, D70, D50 were strongly correlated (Pearsons Correlation Coefficient > 0.65, p < 0.05).
Conclusion
90 Y absorbed dose outcomes in the DOSISPHERE-01 study corresponded closely with [ 99m Tc]Tc-MAA predictive dosimetry, confirming the validity of [ 99m Tc]Tc-MAA for dosimetry-based treatment planning in this clinical scenario. Agreement was maximised using anatomic segmentation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, University Medical Center, Utrecht, 3508 GA, The Netherlands. g.e.m.keane@umcutrecht.nl.
- Boston Scientific Corporation, Marlborough, MA, USA. g.e.m.keane@umcutrecht.nl.
- Assistance Publique Hôpitaux de Paris, Paris, France.
- Department of Radiology, St-Eloi University Hospital, Montpellier, France.
- Département d'Anesthésie Chirurgie et Interventionnel, Interventional Radiology unit, Gustave Roussy Université Paris Saclay, Villejuif, France.
- Boston Scientific Corporation, Marlborough, MA, USA.
Zitieren
APA
Keane, G., Chalaye, J., Guiu, B., Tselikas, L., Fowers, K. D., Boucher, E., Garin, E., Palard, X., & Lam, M. G. E. H. (2026). Predictive value of [99mTc]Tc-MAA SPECT/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8217-8228. https://doi.org/10.1007/s00259-026-08079-8
Vancouver
Keane G, Chalaye J, Guiu B, Tselikas L, Fowers KD, Boucher E, et al. Predictive value of [99mTc]Tc-MAA SPECT/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8217-8228. doi:10.1007/s00259-026-08079-8
BibTeX
@article{Keane2026,
author = {Keane, Grace and Chalaye, J and Guiu, B and Tselikas, L and Fowers, K D and Boucher, E and Garin, E and Palard, X and Lam, M G E H},
title = {Predictive value of [99mTc]Tc-MAA SPECT/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8217--8228},
doi = {10.1007/s00259-026-08079-8}
}
EUVIMED